On 27 March 2025, the trading in Asker Healthcare Group AB’s shares commenced on Nasdaq Stockholm. The final price in the offering was set to SEK 70 per share, equivalent to a valuation of approximately SEK 26.8 billion, post offering.
Asker is a leading provider of medical products and solutions in Europe. Over the past decade, Asker has organically and via acquisitions built a pan-European group with deep knowledge in healthcare, attracting entrepreneurs that together with the Company want to drive progress and support the healthcare system to improve patient outcomes, reduce the total cost of care, and ensure a fair and sustainable value chain. Today, Asker consists of 45 companies in 17 countries with more than 4,000 employees, which brings significant scale and enables knowledge sharing, to the benefit of the Group and the healthcare sector.
Carnegie, Citi and Nordea acted as Joint Global Coordinators and Joint Bookrunners while BNP Paribas and Danske Bank acted as Joint Bookrunners.
Baker McKenzie acted as legal advisor to the Joint Global Coordinators and Joint Bookrunners, with a Capital Markets team consisting of Henric Roth, Joakim Falkner, Oscar Bang, Johanna Flink from Stockholm and Adam Farlow and Charles Farnsworth from London.